Niagen Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	129.42	99.6	83.57	72.05	67.45
Revenue Growth (YoY)	29.95%	19.18%	15.99%	6.82%	13.83%
Cost of Revenue	46.23	38.01	32.79	29.25	25.96
Gross Profit	83.19	61.59	50.78	42.8	41.49
Selling, General & Admin	62.56	47.84	51.42	56.6	64.73
Research & Development	6.33	6.02	4.96	4.83	3.83
Total Operating Expenses	68.89	53.86	56.38	61.43	68.56
Operating Income	14.3	7.73	-5.6	-18.63	-27.07
Interest Income	-	-	-	2.09	-
Other Non-Operating Income (Expense)	2.13	1.13	0.66	0	-0.06
Total Non-Operating Income (Expense)	2.13	1.13	0.66	2.09	-0.06
Pretax Income	16.42	8.86	-4.94	-16.54	-27.13
Provision for Income Taxes	0.81	0.31	0	-	-
Net Income	17.38	8.55	-4.94	-16.54	-27.13
Net Income to Common	17.38	8.55	-4.94	-16.54	-27.13
Net Income Growth	103.30%	-	-	-	-
Shares Outstanding (Basic)	79	76	75	70	67
Shares Outstanding (Diluted)	85	78	75	70	67
Shares Change (YoY)	9.36%	4.19%	7.54%	3.79%	10.02%
EPS (Basic)	0.22	0.11	-0.07	-0.24	-0.40
EPS (Diluted)	0.20	0.11	-0.07	-0.24	-0.40
EPS Growth	81.82%	-	-	-	-
Free Cash Flow	13.21	11.95	6.97	-15.43	-24.57
Free Cash Flow Growth	10.60%	71.42%	-	-	-
Free Cash Flow Per Share	0.15	0.15	0.09	-0.22	-0.37
Gross Margin	64.28%	61.84%	60.76%	59.40%	61.51%
Operating Margin	11.05%	7.76%	-6.70%	-25.85%	-40.14%
Profit Margin	12.06%	8.58%	-5.91%	-22.96%	-40.22%
FCF Margin	10.21%	11.99%	8.34%	-21.42%	-36.43%
EBITDA	15.08	8.54	-4.57	-17.57	-25.96
EBITDA Margin	11.65%	8.57%	-5.47%	-24.39%	-38.49%
EBIT	14.3	7.73	-5.6	-18.63	-27.07
EBIT Margin	11.05%	7.76%	-6.70%	-25.85%	-40.14%
Effective Tax Rate	4.93%	3.44%	0.00%	0.00%	0.00%

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q